Shares in leading radiation detection products developer Kromek (KMK:AIM) surged 12% to 16.8p after the company was awarded a new $6 million contract by the US Department of Defense.The contract forms part of the second phase of DARPA's (Defense Advanced Research Projects Agency) development of a biological threat detection system that is designed to sense, analyse and identify airborne pathogens

UK stocks opened on a weak note on Wednesday led by domestically-focused stocks on worries that the Conservative lead in the polls had reduced, opening up the prospect of a hung parliament. The FTSE 100 index was trading down 10 points or 0.14% at 7,203, while the mid cap index was off 0.45% at 20,667 points.Leading the FTSE 100 fallers was sports fashion company JD Sports Fashion (JD.) after a 24

Investors appear to be regaining confidence after a volatile period last week with markets marching forward across the UK, mainland Europe and Asia on Monday morning, the FTSE 100 climbing 26.4 points higher to 7,040.3 and the FTSE 250 up almost 140 points at 18,729.Industrial components distributor Diploma (DPLM) ticks up 7.3% to £13.90 on strong full year results revealing 9% growth in adjusted

X-ray technology developer Kromek (KMK:AIM) has raised £47m from investors since IPO on 16 October 2013. Sadly, progress has been slow going and the current market value of the business stands at £33.8m, substantially below the £55m capitalisation when joining AIM. The Durham University spin-out still hopes to grow the business into several markets using its own patent-protected Cadmium Zinc Te

Kromek (KMK:AIM) 32.75pGain to date: 21.3%Previous Shares view: Buy at 31.5p, 25 Feb 2016First it was security, now it's healthcare; 2016 has got off to a stellar start for digital x-ray technology kit designer Kromek (KMK:AIM). We covered the $6 million 'dirty bomb' developments on 25 February; the latest agreement takes orders won to $27.6 million in full year to 30 April 2016, this time from a

'Micro caps', the London stock market's smallest quoted companies, are often binary bets. They either make investors lots of money or lose everything. Yet despite their inherent risks, micro caps should form at least a portion of a well-diversified portfolio, since they offer potential for rapid-paced growth and bumper share price gains if you pick the best ones.This is an especially attractive ch

Kromek (KMK:AIM) 31.5pGain to date: 16.7%Original entry price: Buy at 27p, 1 Oct 2015The global terror threat continues to escalate and while that topic is, in general, best discussed outside of these pages, it's encouraging that a little British technology business is helping provide part of the wider solution.Digital x-ray technology kit designer Kromek (KMK:AIM) has been awarded an exclusive de

Extensively used by hospitals (and superheroes), Durham University spin-out Kromek (KMK:AIM) aims to take x-ray technology into new markets using its own patent-protected Cadmium Zinc Telluride (CZT) crystal technology. This is a high-risk play, and it will not suit every investor, but we believe that for those willing to roll the dice there is substantial growth here. Consensus share price target

London stocks open a touch higher in early trade on Friday with the market relatively quiet for corporate news to provide direction ahead of the weekend. The benchmark FTSE 100 index nudges roughly 19 points, or 0.2%, higher 7,077 in early deals, with utility stocks leading the rise, the index having eased off Wednesday's record closing high of 7,096.78.Blue-chips are led higher by water group Sev

Durham University spin-out Kromek (KMK:AIM) has won an important contract extension that could open the way for a substantial new revenue source.The US Defence Advanced Research Projects Agency (DARPA) has broadened its existing agreement with the Sedgefield-based X-ray technology kit developer to help develop an advanced portable detection system for gamma and neutron radiation as part of the US

FTSE 100 fund manager Schroders (SDR) bucks the weak market trend, rising 1% to £24.57, after analysts at RBC Capital Markets set out their reasoning for a punchy £28.00 price target. Analyst Peter Lenardos says the firm should trade in line with peers due to double-digit EPS growth, diversification and the potential for bolt-on acquisitions.Supermarkets titan Tesco (TSCO) ticks 2.85% higher to

It was exactly 163 days after joining AIM via an £15 million initial public offering (IPO) priced at 51p that Kromek (KMK:AIM) stunned the market with a revenue warning. The x-ray technology designer was forced would admit revenue for the period to be 'significantly below current market expectations,' thanks to delayed large contracts and a failure to get its commercial team properly in place.'In

If only x-ray technology could be used to better predict new business. This may be a lament among investors in Kromek (KMK:AIM) after the x-ray technology kit designer issued a huge profit warning today. Not that it was expected to make a pre-tax profit this year to end April, or next to April 2015 either for that matter. So let's settle for revenue warning.While on the cusp of accelerating its co

Having seen its share price obliterated since January, due to investor concerns about unfavourable foreign exchange rates impacting its accounts which are reported in sterling and geopolitical worries due to exposure to the Ukraine and Russia, exhibitions group ITE (ITE) bounces back 2.2% to 194.4p after a reassuring trading update. N+1 Singer analyst Johnathan Barrett comments: 'ITE stock has a h

In 2013 we have benefited from the surge of successful IPOs with names like Bonmarche (BON:AIM), Servelec (SERV), Kromek (KMK:AIM) and Safestyle (SFE). One new issue we supported that has lagged since listing, but which remains very exciting for 2014 is Tungsten (TUNG:AIM).Despite the name, Tungsten actually has nothing to do with metals or mining. Rather, the company is an investment vehicle. The

Bwin.Party looking betterGambler Bwin.Party (BPTY) could be a turnaround story for 2014 after becoming New Jersey's market leader in online poker since November's launch. A positive update (18 Dec) reassures following earlier disappointment. Broker Panmure Gordon says the downside is limited and upside potential is significant. (DC)Lift-off for KromekLooser EU aviation regulations with regard to l

Stockbroker Panmure Gordon has today published its list of top small and mid cap picks for 2014. It features several companies that Shares has discussed in detail over the past months and years including discount alcohol seller Conviviality Retail (CVR:AIM) and online gambling operator GVC (GVC:AIM), both of which are running Shares Plays of the Week.Panmure highlights 13 small and mid cap stocks.

FTSE 100 engineer IMI (IMI) is to return £620 million to shareholders after selling its beverage dispense and merchandising divisions to Berkshire Hathaway (BRK.A:NYSE)-owned Marmon for £690 million. Shareholders will get to choose whether they want the cash as income and/or capital payment. The remaining £70 million proceeds of the sale to Warren Buffett's empire will go to the company's pensi